As Deals Shrink, Indian Companies Ask MNCs To Stay Open For Drug Discovery Partnerships - PharmAsia Summit

SAN FRANCISCO - Consolidation among Big Pharma has resulted in fewer opportunities for smaller companies to out-license newly researched compounds, while the inclination of large companies to selectively work only on "first-to-market" drugs has complicated deal-making for companies with early-stage leads